Somatic delivery of catecholamines in the striatum attenuate Parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats

Experimental Neurology

Volumn 145, Issue 1, 1997, Pages 130-140

  Lindner, Mark D ^a   Plone, Melissa A ^a   Mullins, Ted D ^a   Winn, Shelley R ^a   Chandonait, Susan E ^a   Stott, Jennifer A ^a   Blaney, Thomas J ^a   Sherman, Sandy S ^a   Emerich, Dwaine F ^a  

^a CytoTherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOLAMINE; DOPAMINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; DYSKINESIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOTYPY;

EID: 0031149126     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6456     Document Type: Article

References (88)

1. Aebischer P., Goddard M., Signore A. P., Timpson R. L. Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells. Exp. Neurol. 126:1994;151-158.
2. Aebischer P., Tresco P. A., Winn S. R., Greene L. A., Jaeger C. B. Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line. Exp. Neurol. 111:1991;269-275.
3. Ahlskog J. E., Kelly P. J., Van Heerden J. A., Stoddard S. L., Tyce G. M., Windebank A. J., Bailey P. A., Bell G. N., Blexrud M. D., Carmichael S. W. Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: Clinical outcome and neurochemical studies. Mayo Clin. Proc. 65:1990;305-328.
4. Amalric M., Koob G. F. Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction-time performance in rats. J. Neurosci. 7:1987;2129-2134.
5. Bing G., Notter M. F. D., Hansen J. T., Gash D. M. Comparison of adrenal medullary, carotid body and PC12 cell grafts in 6-OHDA lesioned rats. Brain Res. Bull. 20:1988;399-406.
6. Birkmayer W., Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J. Neural Transm. 37:1975;175-182.
7. Bjorklund A., Dunnett S. B., Stenevi U., Lewis M. E., Iversen S. D. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 199:1980;307-333.
8. Blanchet P. J., Gomezmancilla B., Dipaolo T., Bedard P. J. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia. Fundam. Clin. Pharmacol. 9:1995;434-442.
9. Blunt S., Jenner P., Marsden C. D. The effect of chronic L-Dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencaphalic grafts. Neuroscience. 40:1991;453-464.
10. Bravo G., Potvin L. Estimating the reliability of continuous measures with Cronbach's alpha or the intraclass correlation coefficient: Toward the integration of two traditions. J. Clin. Epidemiol. 44:1991;381-390.
11. Campbell K., Bjorklund A. Neurotransmitter-related gene expression in intrastriatal striatal transplants. 3. Regulation by host cortical and dopaminergic afferents. Mol. Brain Res. 29:1995;273-284.
12. Carey R. J. Chronic L-DOPA treatment in the unilateral 6-OHDA rat: Evidence for behavioral sensitization and biochemical tolerance. Brain Res. 568:1991;205-214.
13. Carey R. J., Pinheirocarrera M., Dai H. L., Tomaz C., Huston J. P. L-DOPA and psychosis: Evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone. Biol. Psychiatry. 38:1995;669-676.
14. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 1988;Lawrence Erlbaum, Hillsdale.
15. Cools A. R. Role of the neostriatal dopaminergic activity in sequencing and selecting behavioural strategies: Facilitation of processes involved in selecting the best strategy in a stressful situation. Behav. Brain Res. 1:1980;361-378.
16. Creese E., Iversen S. D. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res. 55:1973;369-382.
17. Creese I., Burt D. R., Snyder S. H. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science. 197:1977;596-598.
18. Creese I., Iversen S. D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res. 83:1975;419-436.
19. Date I., Felten S. Y., Felten D. L. Cografts of adrenal medulla with peripheral nerve enhance the survivability of transplanted adrenal chromaffin cells and recovery of the host nigrostriatal dopaminergic system in MPTP-treated young adult mice. Brain Res. 537:1990;33-39.
20. Defer G. L., Geny C., Ricolfi F., Fenelon G., Monfort J. C., Remy P., Villafane G., Jeny R., Samson Y., Keravel Y., Gaston A., Degos J. D., Peschanski M., Cesaro P., Nguyen J. P. Long-term outcome of unilaterally transplanted Parkinsonian patients. 1. Clinical approach. Brain. 119:1996;41-50.
21. Delaney P., Fermaglich J. Parkinsonism and levodopa: A five-year experience. J. Clin. Pharmacol. 16:1976;652-659.
22. Dinsmore J., Ratliff J., Deacon T., Pakzaban P., Jacoby D., Galpern W., Isacson O. Embryonic stem cells differentiated in vitro as a novel source of cells for transplantation. Cell Transplant. 5:1996;131-143.
23. Dirocco A., Molinari S. P., Kollmeier B., Yahr M. D. Parkinson's disease: Progression and mortality in the L-DOPA era. Parkinson's Disease. 1996;Lippincott-Raven, Philadelphia. p. 3-11.
24. Dodd D. H., Schultz R. F. Jr. Computational procedures for estimating magnitude of effect for some analysis of variance designs. Psychol. Bull. 79:1973;391-395.
25. Dunnett S. B. Functional repair of striatal systems by neural transplants: Evidence for circuit reconstruction. Behav. Brain Res. 66:1995;133-142.
26. Dunnett S. B., Bjorklund A., Schmidt R. H., Stenevi U., Iversen S. D. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol. Scand. 522:1983;29-37.
27. Dunnett S. B., Bjorklund A., Stenevi U., Iversen S. D. Grafts of embryonic nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res. 229:1981;209-217.
28. Dunnett S. B., Bjorklund A., Stenevi U., Iversen S. D. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res. 215:1981;147-161.
29. Emerich D. F., Frydel B. R., Flanagan T. R., Palmatier M., Winn S. R., Christensen L. Transplantation of polymer encapsulated PC12 cells: Use of chitosan as an immobilization matrix. Cell Transplant. 2:1993;241-249.
30. Emerich D. F., McDermott P. E., Krueger P. M., Frydel B., Sanberg P. R., Winn S. R. Polymer-encapsulated PC12 cells promote recovery of motor function in aged rats. Exp. Neurol. 122:1993;37-47.
31. Emerich D. F., McDermott P. E., Krueger P. M., Winn S. R. Intrastriatal implants of polymer-encapsulated PC12-cells - Effects on motor function in aged rats. Prog. Neuro-Psychopharm. Biol. Psychiat. 18:1994;935-946.
32. Emerich D. F., Winn S. R., Lindner M. D. Continued presence of intrastriatal but not intraventricular polymer-encapsulated PC12 cells is required for alleviation of behavioral deficits in Parkinsonian rodents. Cell Transplant. 5:1996;589-596.
33. Ferre S., Casas M., Cobos A., Garcia C., Jane F., Grau J. M. L-Dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors. Psychopharmacology. 91:1987;254-256.
34. Fisher L. J., Gage F. H. Radical directions in Parkinson's disease. Nature Med. 1:1995;201-203.
35. Freed W. J., Patel-Vaidya U., Geller H. M. Properties of PC12 pheochromocytoma cells transplanted to the adult rat brain. Exp. Brain Res. 63:1986;557-566.
36. Gage F. H. Neuronal stem cells: Their characterization and utilization. Neurobiol. Aging. 15:1994;S191.
37. Gage F. H., Ray J., Fisher L. J. Isolation, characterization, and use of stem cells from the CNS. Annu. Rev. Neurosci. 18:1995;159-192.
38. Goetz C. G., Tanner C. M., Penn R. D., Stebbins G. T., Gilley D. W., Shannon K. M., Klawans H. L., Comella C. L., Wilson R. S., Witt T. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology. 40:1990;273-276.
39. Greene L. A., Tischler A. S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA. 73:1976;2424-2428.
40. Hefti F., Hartikka J., Schlumpf M. Implantation of PC12 cells into the corpus striatum of rats with lesions of the dopaminergic nigrostriatal neurons. Brain Res. 348:1985;283-288.
41. 3. Brain Res. 211:1981;285-292.
42. Hornykiewicz O. Parkinson's disease and its chemotherapy. Biochem. Pharmacol. 24:1975;1061-1065.
43. Kirk R. E. Experimental Design: Procedures for the Behavioral Sciences. 1982;Brooks/Cole, Pacific Grove.
44. Kordower J. H., Freeman T. B., Snow B. J., Vingerhoets F. J. G., Mufson E. J., Sanberg P. R., Hauser R. A., Smith D. A., Nauert G. M., Perl D. P., Olanow C. W. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332:1995;1118-1124.
45. Kordower J. H., Liu Y. T., Winn S., Emerich D. F. Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: A behavioral, neuroanatomical, and neurochemical analysis. Cell Transplant. 4:1995;155-171.
46. Kordower J. H., Rosenstein J. M., Collier T. J., Burke M. A., Chen E. Y., Li J. M., Martel L., Levey A. E., Mufson E. J., Freeman T. B., Olanow C. W. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370:1996;203-230.
47. Langston J. W., Widner H., Goetz C. G., Brooks D., Fahn S., Freeman T., Watts R. Core assessment program for intracerebral transplantations (CAPIT). Movement Disord. 7:1992;2-13.
48. Lindner M. D., Plone M. A., Francis J. M., Blaney T. J., Salamone J. D., Emerich D. F. Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task. Behav. Brain Res. 86:1997;25-40.
49. Lindner M. D., Plone M. A., Francis J. M., Emerich D. F. Validation of a rodent model of Parkinson's disease: Evidence of a therapeutic window for oral Sinemet. Brain Res. Bull. 39:1996;367-372.
50. Lindner M. D., Winn S. R., Baetge E. E., Hammang J. P., Gentile F. T., Doherty E., McDermott P. E., Frydel B., Ullman M. D., Schallert T., Emerich D. F. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp. Neurol. 132:1995;62-76.
51. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K. L., Sawle G., Rothwell J. C., Marsden C. D. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 247:1990;574-577.
52. Lindvall O., Rehncrona S., Brundin P., Gustavii B., Astedt B., Widner H., Lindholm T., Bjorklund A., Leenders K. L., Rothwell J. C. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46:1989;615-631.
53. Lindvall O., Sawle G., Widner H., Rothwell J. C., Bjorklund A., Brooks D., Brundin P., Frackowiak R., Marsden C. D., Odin P., Rehncrona S. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 35:1994;172-180.
54. Lindvall O., Widner H., Rehncrona S., Brundin P., Odin P., Gustavii B., Frackowiak R., Leenders K. L., Sawle G., Rothwell J. C. Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 31:1992;155-165.
55. Luquin M. R., Scipioni O., Vaamonde J., Gershanik O., Obeso J. A. Levodopa-induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification. Movement Disord. 7:1992;117-124.
56. Mandel R. J., Brundin P., Bjorklund A. The importance of graft placement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. Eur. J. Neurosci. 2:1990;888-894.
57. Marshall J. F. Somatosensory inattention after dopamine-depleting intracerebral 6-OHDA injections: Spontaneous recovery and pharmacological control. Brain Res. 177:1979;311-324.
58. Marshall J. F., Berrios N., Sawyer S. Neostriatal dopamine and sensory inattention. J. Comp. Physiol. Psychol. 94:1980;833-846.
59. Marshall J. F., Gotthelf T. Sensory inattention in rats with 6-hydroxydopamine-induced degeneration of ascending dopaminergic neurons: Apomorphine-induced reversal of deficits. Exp. Neurol. 65:1979;398-411.
60. Marshall J. F., Ungerstedt U. Striatal efferent fibers play a role in maintaining rotational behavior in the rat. Science. 198:1977;62-64.
61. Mokry J. Experimental models and behavioural tests used in the study of Parkinson's disease. Physiol. Res. 44:1995;143-150.
62. Montoya C. P., Astell S., Dunnett S. B. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Prog. Brain Res. 82:1990;459-466.
63. Mouradian M. M., Heuser I. J. E., Baronti F., Chase T. N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27:1990;18-23.
64. Mouradian M. M., Heuser I. J. E., Baronti F., Fabbrini G., Juncos J. L., Chase T. N. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25:1989;523-526.
65. Nutt J. G., Holford N. H. G. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann. Neurol. 39:1996;561-573.
66. Obeso J. A., Grandas F., Herrero M. T., Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur. J. Neurosci. 6:1994;889-897.
67. Olanow C. W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
68. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15:1995;3863-3875.
69. Perlow M. J., Freed W. J., Hoffer B. J., Seiger A., Olson L., Wyatt R. J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science. 204:1979;643-647.
70. Rinne U. K., Lonnberg P., Koskinen V. Dopamine receptors in the parkinsonian brain. J. Neural Transm. 51:1981;97-106.
71. SAS Institute Inc. 1989, SAS/STAT User's Guide, Version 6, Vol. 1, SAS Institute Inc. Cary, NC.
72. Schallert T., De Ryck M., Whishaw I. Q., Ramirez V. D., Teitelbaum P. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp. Neurol. 64:1979;33-43.
73. Schwab R. S., Zieper I. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease. Psychiatria Neurol. 150:1965;345-357.
74. Spirduso W. W., Gilliam P. E., Schallert T., Upchurch M., Vaughn D. M., Wilcox R. E. Reactive capacity: A sensitive behavioral marker of movement initiation and nigrostriatal dopamine function. Brain Res. 335:1985;45-54.
75. Steece-Collier K., Collier T. J., Sladek C. D., Sladek J. R. Jr. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp. Neurol. 110:1990;201-208.
76. Steece-Collier K., Yurek D. M., Collier T. J., Junn F. S., Sladek J. R. The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing. Brain Res. 676:1995;404-408.
77. Stenevi U., Bjorklund A., Dunnett S. B. Functional reinnervation of the denervated neostriatum by nigral transplants. Peptides. 1:1980;111-116.
78. Stocchi F., Bonamartini A., Vacca L., Ruggieri S. Motor fluctuations in levodopa treatment: Clinical pharmacology. Eur. Neurol. 36:1996;38-42.
79. Stromberg I., Herrera-Marschitz M., Ungerstedt U., Ebendal T., Olson L. Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior. Exp. Brain Res. 60:1985;335-349.
80. Svendsen C. N., Clarke D. J., Rosser A. E., Dunnett S. B. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp. Neurol. 137:1996;376-388.
81. Tan S. A., Aebischer P. The problems of delivering neuroactive molecules to the CNS. Bock G. R., Goode J. A. Growth Factors as Drugs for Neurological and Sensory Disorders. 1996;211-236 Wiley, Chichester.
82. Tresco P. A., Winn S. R., Aebischer P. Polymer encapsulated neurotransmitter secreting cells: Potential treatment for Parkinson's disease. ASAIO J. 38:1992;17-23.
83. Tresco P. A., Winn S. R., Tan S., Jaeger C. B., Greene L. A., Aebischer P. Polymer-encapsulated PC12 cells: Long-term survival and associated reduction in lesion-induced rotational behavior. Cell Transplant. 1:1992;255-264.
84. Ungerstedt U., Ljungberg T., Greg G. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv. Neurol. 5:1974;421-426.
85. Weiss S., Reynolds B. A., Vescovi A. L., Morshead C., Craig C. G., Vanderkooy D. Is there a neural stem cell in the mammalian forebrain. Trends Neurosci. 19:1996;387-393.
86. Winn S. R., Tresco P. A., Zielinski B., Greene L. A., Jaeger C. B., Aebischer P. Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells. Exp. Neurol. 113:1991;322-329.
87. Yurek D. M., Steece-Collier K., Collier T. J., Sladek J. R. Jr. Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting. Exp. Brain Res. 86:1991;97-107.
88. Zabek M., Mazurowski W., Dymecki J., Stelmachow J., Zawada E. A long term follow-up of fetal dopaminergic neurons transplantation into the brain of three parkinsonian patients. Restor Neurol. Neurosci. 6:1994;97-106.